<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03276156</url>
  </required_header>
  <id_info>
    <org_study_id>Ahead-G001</org_study_id>
    <nct_id>NCT03276156</nct_id>
  </id_info>
  <brief_title>Apatinib in Combination With S-1 as Second-Line Treatment in Patients With Advanced Gastric Cancer</brief_title>
  <official_title>Apatinib in Combination With S-1 as Second-Line Treatment in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Zhejiang Cancer Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the maximum tolerated dose (MTD)and safety of
      Apatinib combined with S-1 as Second-line therapy for patients with advanced gastric or
      gastroesophageal junction adenocarcinoma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 23, 2016</start_date>
  <completion_date type="Anticipated">February 22, 2018</completion_date>
  <primary_completion_date type="Anticipated">February 22, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival(PFS)</measure>
    <time_frame>Event driven, an expected average of 4 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>An expected average of 4 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival(OS)</measure>
    <time_frame>An expected average of 12months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate(DCR)</measure>
    <time_frame>An expected average of 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate(ORR)</measure>
    <time_frame>An expected average of 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life(QoL)</measure>
    <time_frame>An expected average of 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Apatinib plus S-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apatinib (425/500/675/750mg,qd,p.o.) concomitantly with S-1 (80mg to 120 mg, qd,days1-14, q3w, p.o.)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib plus S-1</intervention_name>
    <description>Drug:Apatinib (425 mg/d) + S-1 (80mg to 120 mg);Drug:Apatinib (500 mg/d) + S-1 (80mg to 120 mg);Drug:Apatinib (675mg/d) + S-1 (80mg to 120 mg);Drug:Apatinib (750 mg/d) + S-1 (80mg to 120 mg);</description>
    <arm_group_label>Apatinib plus S-1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Fully informed consent prior to any specific research procedure.

          2. Adult patients, aged ≥18 years;

          3. Imaging test confirmed the progression after first-line treatment of advanced gastric
             adenocarcinoma or Gastroesophageal Junction Adenocarcinoma.

               -  S-1 was not used in the first-line treatment

               -  If patient relapse in 6 months after adjuvant chemotherapy or neoadjuvant
                  chemotherapy, the adjuvant chemotherapy or neoadjuvant chemotherapy was regarded
                  as the first-line treatment.

          4. Adjuvant chemotherapy or neoadjuvant chemotherapy was allowed if the first-line
             treatment started beyond 6 months after the end of previous treatment.

          5. During the research ,patient should be willing and be able to follow the process
             treatment ,follow up and tests.

          6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 1.

          7. Survival expectation ≥ 16 weeks from the planned first dosing .

          8. During the 28 days prior to the first dosing, hematological, biochemical and Organ
             Functions:HB ≥ 9.0 g/dL, ANC ≥ 1.5×109/L,WBC＞3×109/L， PLT ≥ 100×109/L, BIL &lt; 1.5×ULN,
             ALT or AST &lt; 2.5×ULN (or &lt; 5×ULN in patients with liver metastases), Serum Cr ≤
             1.5×ULN;

          9. Lesions ,measurable and/or unmeasurable,at least one,can be assessed by imaging during
             the baseline and follow-up measurement.

               -  Localized mass in gastric or Gastroesophageal Junction belongs to unmeasurable
                  Lesions.

         10. Women, those postmenopausal or of child-bearing age, but the pregnancy test results
             (serum or urine) within 28 days before treatment is negative, and the results should
             be confirmed in day 1 of the treatment.

               -  Postmenopausal women are defined as :woman's menstrual periods have ceased for 1
                  year or longer after exogenous hormone therapy;

               -  Women, aged＞50years,serum LH and FSH level show a postmenopause;

               -  Woman has radiation induced ovarian failure,and gone without a period for over 12
                  consecutive months;

               -  Woman has chemotherapy-induced menopause and gone without a period for over 12
                  consecutive months;

               -  sterilization operation( hysterectomy or bilateral oophorectomy)

        Exclusion Criteria:

          1. Has participated in another clinical trial in progress.

          2. Has received more than one chemotherapy regimens after disease progression(except for
             those who has receiced adjuvant chemotherapy or neoadjuvant chemotherapy 6 months or
             longer)

          3. Previous therapy with S-1

          4. Has received VEGFR inhibitor, such as Sorafenib,Sunitinib .

          5. Has another primary tumor,but adequately treated non-melanoma skin cancer ,
             effectively treated carcinoma in situ of cervix and other well handled cancer over 5
             years were not covered.

          6. Has difficulty in swallowing

          7. Has taken experimental drugs within 14 days before randomly assign.( For different
             drug characteristics, the interval can be longer)

          8. History of any chemotherapy, radiotherapy,the last administration should finish within
             3 weeks prior to trial first drug administration( For different drug characteristics,
             the interval can be longer). If steady dose of diphosphate or denosumab is necessary
             for the treatment of bone metastases,the administration should start 3-4weeks prior to
             the study .

          9. Patients with poor-controlled arterial hypertension (systolic blood pressure &gt; 140
             mmHg or diastolic blood pressure &gt; 90 mm Hg) despite standard medical management;
             Coronary heart disease greater than Class I, arrhythmia greater than Class I
             (including QT interval prolongation, for man &gt; 450 ms, for woman &gt; 470 ms), and
             cardiac dysfunction greater than Class I;

         10. Has persistent toxicity (exclude alopecia )of previous treatment ,CTCAE＞1.

         11. Has intestinal obstruction or upper gastrointestinal hemorrhage(CTCAE 3 or 4) within 4
             weeks prior to randomly assign.

         12. Abnormal coagulation function (INR &gt; 1.5×ULN, APTT &gt; 1.5×ULN), with tendency of bleed;

         13. Has symptom of brain metastases and the tendency out of control,but imaging confirmed
             is not required.If steady dose of Glucocorticoid is necessary for the treatment,the
             administration should be started ＞4weeks prior to the study . Patients with spinal
             cord compression received definite treatment and the situation had been proven stable
             in 28days .

         14. Has surgery within 2 weeks prior to the study. Eligible patients should recovered from
             any major surgery.

         15. Subjects that are unable to swallow tablets, chronic diarrhea ,or intestinal
             obstruction;

         16. Subjects with a clear tendency of gastrointestinal bleeding;

         17. Pregnant or lactating women;

         18. Other conditions regimented at investigators' discretion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Haijun Zhong</last_name>
    <phone>0571-88122058</phone>
    <email>ZHJ1712@aliyun.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 6, 2017</study_first_submitted>
  <study_first_submitted_qc>September 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 8, 2017</study_first_posted>
  <last_update_submitted>September 6, 2017</last_update_submitted>
  <last_update_submitted_qc>September 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

